Key result
Administration of a single 7.2 mg dose of recombinant factor VIIa for persistent bleeding during LVAD implantation in a patient with HIT was immediately followed by acute left atrial thrombus formation.
Case Report (n=1)
Recombinant factor VIIa administration for refractory bleeding during LVAD implantation in a patient with HIT may precipitate acute left atrial thrombus formation.
Caution with rFVIIa for bleeding in LVAD implantation with HIT; leaves open thrombotic risks and alternatives for prospective study.
In Brief We present a patient with end-stage heart failure and heparin-induced thrombocytopenia Type II, who required cardiopulmonary bypass (CPB) during a repeat implantation of a left ventricular assist device for long-term circulatory support. Bivalirudin was selected for anticoagulation during CPB, with concomitant infusion of aprotinin, in an effort to ameliorate blood loss. Nonetheless, profuse bleeding after CPB required massive transfusion of packed red blood cells, multiple coagulation factors, and platelets. Because of persistent bleeding, a single dose of recombinant factor VIIa (rFVIIa, 7.2 mg) was administered as rescue therapy. Within minutes, a large left atrial thrombus was detected by transesophageal echocardiography. We believe this is the first documentation of acute left atrial thrombus formation immediately after a single dose of recombinant factor VIIa administration during a left ventricular assist device implantation. IMPLICATIONS: A patient with heparin-induced thrombocytopenia who required repeat implantation of a left ventricular assist device underwent cardiopulmonary bypass with bivalirudin for anticoagulation. Profuse bleeding after surgery was treated with massive transfusion therapy, recombinant factor VIIa, and was complicated by an acute left atrial thrombus.
No takes yet. Share an insight, caveat, or question.
Apostolidou et al. (2008) conducted a case report in End-stage heart failure and heparin-induced thrombocytopenia Type II (n=1). Recombinant factor VIIa (rFVIIa) was evaluated on Acute left atrial thrombus formation. Administration of a single 7.2 mg dose of recombinant factor VIIa for persistent bleeding during LVAD implantation in a patient with HIT was immediately followed by acute left atrial thrombus formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: